


New muscular dystrophy drug's chances for approval improve

22 April 2014



A new drug to treat Duchenne muscular dystrophy may be closer to becoming the first approved treatment for the disease.

(HealthDay)—A new drug to treat Duchenne muscular dystrophy may be closer to becoming the first approved treatment for the disease.

Eteplirsen was created to treat Duchenne muscular dystrophy, which affects about one in 3,500 boys worldwide. The drug seemed to be on track for swift approval from the U.S. Food and Drug Administration, but that effort stalled late last year after a similar type of [treatment](#) for the disease failed in a clinical trial, the *Washington Post* reported.

However, Massachusetts-based Sarepta Therapeutics said Monday that FDA officials outlined a potential way forward for the drug and said they may consider it for accelerated approval.

"This provides the opportunity to get the drug approved and in the hands of all the boys who can benefit from it sometime in 2015," Sarepta chief executive officer Chris Garabedian told the *Post*.

Copyright © 2014 [HealthDay](#). All rights reserved.

APA citation: New muscular dystrophy drug's chances for approval improve (2014, April 22) retrieved 11 October 2022 from <https://medicalxpress.com/news/2014-04-muscular-dystrophy-drug-chances.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no

part may be reproduced without the written permission. The content is provided for information purposes only.